Veracyte, a leading cancer diagnostics company, has revealed that eight abstracts featuring findings from its Decipher Prostate and Decipher Bladder genomic classifiers will be showcased at the ASCO annual meeting. The presentations aim to enhance understanding of which patients with prostate or bladder cancer are more likely to respond to specific therapies based on their tumours’ molecular characteristics.
Key Points
- Eight abstracts from Veracyte will be presented at the ASCO meeting on May 30-June 3 in Chicago.
- Findings reveal the potential for personalised therapy selections based on molecular makeup.
- Significant results show that patients with PTEN-inactive metastatic prostate cancer benefit more from docetaxel chemotherapy.
- The Decipher GRID tool provides essential genomic data, advancing prostate and bladder cancer research.
- Interim results from the SURE-02 trial suggest new treatment approaches for muscle-invasive bladder cancer.
Why should I read this?
If you’re keen on staying ahead in the cancer research game (who isn’t, right?), this article is a must-read! It presents fresh insights from Veracyte that could revolutionise treatment plans for prostate and bladder cancer patients. Get the scoop on cutting-edge research that might just influence the next steps in personalised cancer care. We’ve done the legwork for you, so dive right in!